|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/48 | (2006.01) |
| A61K 38/4846 | (2013.01) | ||
| A61P 7/04 | (2006.01) | ||
| C12Y 304/21021 | (2013.01) | ||
| A61P 7/04 | (2018.01) |
| (11) | Patento numeris | 3833381 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 20762011.3 |
| Europos patento paraiškos padavimo data | 2020-08-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2021-06-16 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2022-08-03 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2020/046577 |
| Data | 2020-08-15 |
| (87) | Numeris | WO 2021/030787 |
| Data | 2021-02-18 |
| (30) | Numeris | Data | Šalis |
| 201962887599 P | 2019-08-15 | US | |
| 202062970152 P | 2020-02-04 | US | |
| 202063010656 P | 2020-04-15 | US |
| (72) |
BLOUSE, Grant E. , US
KNUDSEN, Tom , US
LEVY, Howard , US
|
| (73) |
Catalyst Biosciences, Inc. ,
611 Gateway Blvd., Suite 710, South San Francisco, CA 94080,
US
|
| (54) | MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION |
| MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION |